EU and US could reach trade deal this weekend - Reuters
WALTHAM, Mass. - Thermo Fisher Scientific Inc. (NYSE: TMO), a prominent provider of scientific instrumentation, reagents, and consumables, has declared a quarterly cash dividend. The company’s Board of Directors has authorized a payment of $0.43 per common share, which is scheduled for distribution on July 15, 2025, to shareholders who are on record as of June 13, 2025. According to InvestingPro data, TMO has maintained dividend payments for 14 consecutive years and has raised its dividend for 7 consecutive years, demonstrating a strong commitment to shareholder returns.
The announcement reflects Thermo Fisher’s ongoing commitment to delivering value to its shareholders. Known for its extensive portfolio of products and services, the company supports a wide range of customers involved in the healthcare sector, including life sciences research, laboratory productivity, diagnostics, and the development of therapies. With a market capitalization of $150 billion and annual revenue of $42.9 billion, TMO maintains a solid gross profit margin of 41.4%.
Thermo Fisher Scientific has established a significant presence in the scientific community, with an extensive array of brands under its umbrella, such as Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon, and PPD. These brands are recognized for their contribution to advancing scientific research and healthcare.
The company’s financial strength is evidenced by its annual revenue, which exceeds $40 billion. The dividend payout is part of Thermo Fisher’s financial strategy to share its success with its investors, reflecting confidence in its financial position and future prospects. Currently trading near its 52-week low, InvestingPro analysis reveals 8+ additional exclusive insights about TMO’s valuation and growth potential, available to subscribers.
Investors and shareholders of Thermo Fisher Scientific can expect the dividend to be paid in mid-July, following the established record date in June. This action by the Board of Directors is in line with the company’s policy of providing consistent returns to its shareholders. The company maintains a healthy financial profile with a strong Altman Z-Score of 6.11, indicating solid financial stability. For comprehensive analysis and detailed metrics, investors can access TMO’s complete Pro Research Report, part of InvestingPro’s coverage of 1,400+ top US stocks.
The information regarding the dividend is based on a press release statement from Thermo Fisher Scientific Inc.
In other recent news, Thermo Fisher Scientific reported its first-quarter 2025 financial results, exceeding analysts’ expectations. The company achieved an adjusted earnings per share (EPS) of $5.15, slightly above the forecast of $5.11, and recorded revenue of $10.36 billion, surpassing the anticipated $10.23 billion. Despite this strong performance, Scotiabank adjusted its price target for Thermo Fisher from $650 to $605, maintaining a Sector Perform rating, citing macroeconomic challenges and newly imposed tariffs as factors influencing the company’s outlook. Additionally, Thermo Fisher announced a significant $2 billion investment in its U.S. operations over the next four years, with plans to enhance biopharmaceutical manufacturing and research and development. The company also reached a definitive agreement to acquire Solventum’s purification and filtration business for $4.1 billion, aiming to expand its capabilities in the bioproduction market. These developments reflect Thermo Fisher’s strategic initiatives to navigate current economic conditions and capitalize on long-term growth opportunities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.